Comprehensive assessment of serum 3′-tRFArg as a novel diagnostic biomarker for gastric cancer

IF 5 2区 医学 Q2 Medicine
Rui Ding , Yang Li , Yu Zhang , Xun Li , Yunjian Song , Xinliang Gu , Xianjuan Shen , Shaoqing Ju
{"title":"Comprehensive assessment of serum 3′-tRFArg as a novel diagnostic biomarker for gastric cancer","authors":"Rui Ding ,&nbsp;Yang Li ,&nbsp;Yu Zhang ,&nbsp;Xun Li ,&nbsp;Yunjian Song ,&nbsp;Xinliang Gu ,&nbsp;Xianjuan Shen ,&nbsp;Shaoqing Ju","doi":"10.1016/j.tranon.2025.102338","DOIUrl":null,"url":null,"abstract":"<div><div>Gastric cancer is one of the malignant tumors with the highest morbidity and mortality rates worldwide. Yet, there is a lack of diagnostic markers with high sensitivity in the clinic. tRNA-derived small RNAs are a novel type of non-coding small RNAs, which are abundant in tumor cells and body fluids. In this study, we explored the potential of 3′-tRF<sup>Arg</sup> as a tumor marker for the diagnosis of GC. Differential expression of 3′-tRF<sup>Arg</sup> was screened by high-throughput sequencing, and Quantitative real-time PCR confirmed its low expression in GC serum with good stability. Differential expression of serum 3′-tRF<sup>Arg</sup> could distinguish between GC patients, gastritis patients, and healthy donors and was significantly correlated with clinical pathological features such as tumor differentiation, lymph node metastasis, and TNM staging. The receiver operating characteristic curve showed that 3′-tRF<sup>Arg</sup> had a higher diagnostic value compared with conventional biomarkers, especially in the diagnosis of early gastric cancer. In conclusion, our results suggest that 3′-tRF<sup>Arg</sup> can serve as a highly sensitive biomarker with a certain value for monitoring tumor development and prognosis.</div></div>","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":"54 ","pages":"Article 102338"},"PeriodicalIF":5.0000,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1936523325000695","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Gastric cancer is one of the malignant tumors with the highest morbidity and mortality rates worldwide. Yet, there is a lack of diagnostic markers with high sensitivity in the clinic. tRNA-derived small RNAs are a novel type of non-coding small RNAs, which are abundant in tumor cells and body fluids. In this study, we explored the potential of 3′-tRFArg as a tumor marker for the diagnosis of GC. Differential expression of 3′-tRFArg was screened by high-throughput sequencing, and Quantitative real-time PCR confirmed its low expression in GC serum with good stability. Differential expression of serum 3′-tRFArg could distinguish between GC patients, gastritis patients, and healthy donors and was significantly correlated with clinical pathological features such as tumor differentiation, lymph node metastasis, and TNM staging. The receiver operating characteristic curve showed that 3′-tRFArg had a higher diagnostic value compared with conventional biomarkers, especially in the diagnosis of early gastric cancer. In conclusion, our results suggest that 3′-tRFArg can serve as a highly sensitive biomarker with a certain value for monitoring tumor development and prognosis.
血清3′-tRFArg作为胃癌新诊断生物标志物的综合评价
胃癌是世界上发病率和死亡率最高的恶性肿瘤之一。然而,临床上缺乏高灵敏度的诊断标志物。trna衍生的小rna是一种新型的非编码小rna,在肿瘤细胞和体液中大量存在。在本研究中,我们探讨了3 ' -tRFArg作为胃癌诊断肿瘤标志物的潜力。通过高通量测序筛选3′-tRFArg的差异表达,实时荧光定量PCR证实其在GC血清中低表达,稳定性好。血清3′-tRFArg的差异表达可以区分胃癌患者、胃炎患者和健康供者,并与肿瘤分化、淋巴结转移、TNM分期等临床病理特征显著相关。受试者工作特征曲线显示,3′-tRFArg与常规生物标志物相比具有更高的诊断价值,特别是在早期胃癌的诊断中。综上所述,我们的研究结果表明,3 ' -tRFArg可以作为一种高度敏感的生物标志物,在监测肿瘤的发展和预后方面具有一定的价值。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
8.40
自引率
2.00%
发文量
314
审稿时长
54 days
期刊介绍: Translational Oncology publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of oncology patients. Translational Oncology will publish laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer. Peer reviewed manuscript types include Original Reports, Reviews and Editorials.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信